Patients, caregivers, and others interested in lung cancer research gathered at The RiverMarket Kitchen and Bar in Tarrytown, NY on April 13 to hear about the latest developments and important topics in lung cancer. LCRF Together New York offered an opportunity for the community to connect while learning about promising therapies for treatment. Brendon Stiles, MD, and Balazs Halmos, MD, MS, from Montefiore Einstein Comprehensive Cancer Center had a lively discussion with the group and moderator Isabel Preeshagul, DO, MBS, Memorial Sloan Kettering Cancer Center. Dr. Stiles is the Vice Cha ..read more

April 2024 Caroline with her boys Caroline, a nurse practitioner who lives in Louisiana, was more familiar with lung cancer than she cared to be. “About 15 years ago, my maternal aunt was diagnosed with stage 4 lung cancer – in her 40s – and died a year later. And she was a never smoker, very healthy,” she explained. “We all thought, ‘okay, that’s random.’ Fast forward to 2021, my maternal grandmother was also diagnosed with stage 4 lung cancer. Another never smoker. Thankfully, my grandmother lives in Houston and got into MD Anderson. They mentioned the EGFR mutation, so she got tested and w ..read more

For our April #TogetherSeparately livestream talk, Julia Rotow, MD, and Isabel Preeshagul, DO, MBS, discussed resources available to patients and caregivers, assembling and managing a care team, and questions to ask at appointments. Dr. Rotow is Clinical Director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, and Assistant Professor of Medicine, Harvard Medical School. Watch the recording below. The post #TogetherSeparately: Lung Cancer from Day 1 and Beyond appeared first on Lung Cancer Research Foundation ..read more

The good news The FDA recently granted approval to tepotinib for the treatment of advanced non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations. Why it’s important MET alterations occur in 3-4% of patients with NSCLC, and those alterations are responsible for driving the development of the cancer. Patients who have MET exon 14 skipping alterations are typically older individuals at 70 years or greater. The Vision trial was a Phase 2 study that evaluated tepotinib in different groups of patients. In those with exon 14 skipping alterations who were not previously treated, 5 ..read more

Meet the newest member of LCRF’s science team, and hear a quick update on the foundation’s research program as well as news from the lung cancer space. Watch the video below. Featured: Aubrey Rhodes, LCRF Executive Director Dhru Deb, PhD, Senior Director, Research & Administration Antoinette (Toni) Wozniak, MD, Chief Scientific Officer The post Science UpdateSpring 2024 appeared first on Lung Cancer Research Foundation ..read more

By Jeff Stibelman March 2024 I was first diagnosed with cancer of the cervical spine on January 1, 2017, after experiencing very severe nerve pain down my whole right side. Thankfully, due to the sensitivity of what was to be my operation, my doctor sent me to one of the best surgeons in the country at USC Keck MD Center, LA, California. At that time I was told in the beginning it was a schwannoma, a non-cancerous lesion, but it was on my main nerve, hence the excruciating pain, affecting my whole right side. I had to wait for weeks with a lot of pain, since they thought it was benign. I fina ..read more

Foundation honors Mark G. Kris, MD NEW YORK, NY (April 2, 2024) – The Lung Cancer Research Foundation (LCRF) is pleased to announce Dr. Mark G. Kris as its honoree for the 3rd annual Evening of Innovation Gala, which will be held on September 24, 2024 at the Metropolitan Club in Manhattan. Members of LCRF’s Board of Directors and Gala Committee are committed to showcasing LCRF’s impact through recognition of an individual whose support of the organization and the field of lung cancer research is unparalleled, and someone who exemplifies the spirit of LCRF to improve the lives of persons with ..read more

March 30 is National Doctors’ Day, and once again we invited you to send thank you messages to the physicians who have made a difference in your life. Here are a few of the kudos you shared with your inspiring doctors! Thank you to doctors everywhere who are using the results of lung cancer research to give their patients better, longer lives. It’s never too late to support research in honor of your own doctor. Make your own tribute here. To Mohamed Mohamed, MD, Wesley Long Cancer Center “Thank you, Dr. M, for taking this difficult journey with me, being sensitive to my needs, while still ..read more

By Marley Coxe March 2024 “Sure, I’m tired, I’m a mom – it comes with the job. We all have days we’re exhausted.” “I just got over being pretty sick, so my lingering cough must be the illness leaving.” “It’s the beginning of spring; allergies are in season.” “This nausea must be my anxiety. My grandmother just passed away – I need to take the time to process and mourn.” “I’m so out of breath – if I would get myself into better shape, these inclines wouldn’t be so hard to walk up.” These were the excuses I told myself. Marley with her boys Looking back, my symptoms started around February last ..read more

The good news The FDA recently approved Osimertinib combined with chemotherapy for the initial treatment of advanced EGFR-mutated non-small cell lung cancer (NSCLC) based on the results of the FLAURA2 trial. Why it’s important Osimertinib, which is a newer generation oral inhibitor of EGFR, has improved the treatment of EGFR-mutated lung cancer but unfortunately it is not curative for most patients. FLAURA2 was a large, international trial that treated over five hundred patients with advanced EGFR-mutated NSCLC with Osimertinib alone or combined with chemotherapy. The patients treated with O ..read more